Ibrutinib gains NICE approval for use in CLL

NICE has published guidance recommending the use of ibrutinib as an option for treating chronic lymphocytic leukaemia (CLL) in adults who have had at least one prior therapy, or who have a 17p deletion or TP53 mutation and in whom chemo-immunotherapy is unsuitable.

The NICE guidance stipulates that ibrutinib must be provided with the discount agreed in the patient access scheme.

Ibrutinib (Imbruvica) is a protein kinase inhibitor also indicated for use as monotherapy in the treatment of adults with relapsed or refractory mantle cell lymphoma and the treatment of Waldenström's macroglobulinaemia in adults who have received at least one prior therapy, or as first-line therapy in those unsuitable for chemo-immunotherapy.

The drug is also licensed for use alone or in combination with bendamustine and rituximab for the treatment of CLL in adults who have received at least one prior therapy.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases